Peptide (Adjuvant) Combination Patients enrolled Phase of the study Clinical results References 100 mer MUC1 (SB-AS2 adjuvant) 16 with resected or locally advanced PC I Detectable MUC1-specific humoral and T-cell responses were detected in some patients. [ 102] 100 mer MUC1 (incomplete Freund’s adjuvant) 6 with advanced PC I One patient showed a tendency for increased circulating anti-MUC1 IgG antibody. [ 103] VEGFR2-169 Gemcitabine 21 with unresectable PC I Specific cytotoxic T lymphocytes (CTL) reacting to the VEGFR2-169 peptide were induced in 11 (61%) of the 18 evaluable patients. The disease control rate was 67%, and the median overall survival time was 8.7 months. [ 101] Telomerase (GM-CSF) 48 with advanced PC I/II Immune responses were observed in 24 of 38 evaluable patients. One-year survival for the evaluable patients in the intermediate dose group was 25%. [ 105] Mutant K-ras (GM-CSF) 10 with resected and 38 with advanced PC I/II Immune response to the peptide vaccine showed prolonged survival compared to nonresponders. K-ras-specific T cells were selectively accumulated in the tumor. [ 77] Mutant K-ras (GM-CSF) 24 with resected PC Pilot study Vaccination proved to be safe and tolerable with however no elicitable immunogenicity and unproven efficacy. [ 107] 13 mer mutant ras 5 with PC and 7 with colorectal cancer II This vaccine is safe, can induce specific immune responses, and it appears to have a positive outcome in overall survival. The five pancreatic cancer patients have shown a mean disease-free survival (DFS) of 35.2+ months and a mean overall survival (OS) of 44.4+ months. [ 108] Mutant ras long peptide 23 with resected PC I 17 of 20 evaluable patients (85%) responded immunologically to the vaccine. Ten-year survival was 20% (four patients out of 20 evaluable). [ 111] Surviving 1 with liver metastasis of PC refractory to gemcitabine Case report The patient initially underwent partial remission of liver metastasis which proceeded after 6 months into a complete remission with duration of 8 months. [ 17] Personalized peptide vaccine Gemcitabine 11 with advanced PC I The 6- and 12-month survival rates for patients who received >3 vaccinations (
) were 80% and 20%, respectively.